Latest news with #JBChemicals&Pharmaceuticals
Business Standard
4 days ago
- Business
- Business Standard
J B Chemicals & Pharmaceuticals allots 1.12 lakh equity shares under ESOS
J B Chemicals & Pharmaceuticals has allotted 112,990 fully paid up equity shares of Re. 1/- each of the Company, to certain employees on exercise of stock options granted to them pursuant to JBCPL Employee Stock Option Scheme, 2021. An amount of Rs. 5,16,30,125 has been realised on exercise of 112,990 stock options. Consequently, the issued, subscribed and paid up capital has increased from 15,58,60,544 equity shares of Re. 1 each to 15,59,73,534 equity shares of Re. 1 each.
Business Standard
15-05-2025
- Business
- Business Standard
J B Chemicals & Pharmaceuticals consolidated net profit rises 15.48% in the March 2025 quarter
Sales rise 10.18% to Rs 949.48 crore Net profit of J B Chemicals & Pharmaceuticals rose 15.48% to Rs 145.69 crore in the quarter ended March 2025 as against Rs 126.16 crore during the previous quarter ended March 2024. Sales rose 10.18% to Rs 949.48 crore in the quarter ended March 2025 as against Rs 861.73 crore during the previous quarter ended March 2024. For the full year,net profit rose 19.35% to Rs 659.58 crore in the year ended March 2025 as against Rs 552.63 crore during the previous year ended March 2024. Sales rose 12.45% to Rs 3917.99 crore in the year ended March 2025 as against Rs 3484.18 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 949.48861.73 10 3917.993484.18 12 OPM % 23.8522.99 - 26.3425.74 - PBDT 239.47205.34 17 1058.43889.83 19 PBT 193.03164.60 17 887.39751.51 18 NP 145.69126.16 15 659.58552.63 19
Mint
02-05-2025
- Business
- Mint
Best stocks to buy today: Raja Venkatraman recommends three stocks for 2 May
Sensex and Nifty 50 ended a choppy trading session nearly unchanged on Wednesday, 30 April, as market sentiment remained subdued due to geopolitical tensions and cautious guidance from Bajaj Finance. Although the domestic market has rebounded by 10% from its April lows—driven by strong foreign institutional inflows and India's perceived relative insulation from global trade disputes—escalating geopolitical concerns have tempered risk appetite. Buy JB Chemicals & Pharmaceuticals (current market price ₹ 1612.40) Also Read | Mint Primer: What IT companies' Q4 show means for investors Also Read: FPIs bet on limited Nifty movement amid simmering India-Pakistan tensions Indian benchmark indices, Sensex and Nifty 50 , ended a choppy trading session nearly unchanged as market sentiment remained subdued due to geopolitical tensions and cautious guidance from Bajaj Finance. By the close, the Sensex slipped 0.06% (46.14 points) to 80,242.24, while the Nifty inched down 0.01% (1.75 points) to finish at 24,334.20. Although the domestic market has rebounded by 10% from its April lows—driven by strong foreign institutional inflows and India's perceived relative insulation from global trade disputes—escalating geopolitical concerns have tempered risk appetite. The market did its best over the last seven days to climb higher, but has not managed. However, the trends have managed to arrest any kind of selling pressure that emerged thus indicating that the overall markets continue to remain positive. A small body candle once again highlights the contemplation that we witnessed in Nifty clearly aimed to erase the nervousness in Nifty that had been holding back the revival. After some volatile movements, the Nifty managed to give a better closing. Important support to watch out for is a range that is getting built based on the option data between 24200 and 24500, hinting at some strong Put writing emerging. Based on PCR data, the negative bias is not ruled out yet, and the short covering action that may follow based on global cues could help the market rise rapidly. As a rise is being attempted, resistance remains at 24500 with the Max Pain Point at 24300 continuing to be a supporting part. The levels around 24500 would be the next hurdle that the index should attempt to conquer on the way up. The indices seem to have been caught in a range and this can create some confusion at the moment. The positive trends that are emerging at lower level are highlighting that the potential to step up is increasing by the day. As the highs around 24500 are continuing to be challenged the probability of scaling beyond this zone looks probable. We have been witnessing some consolidation and the range bound around 24250 to 24350 is witnessing some strong Put writing. The base that is getting built is hinting at the Max Pain Point around 24350 would be a key level to watch out for. A move above this area is needed hence it would be a testing phase for the trends ahead. Some heavy Put writing has emerged at 24300. The Put Call Ratio (PCR) has now moved to 1 in Nifty and Bank Nifty giving a sense of discomfort to the bullish camp as we head into the next trading session. View all stories by Raja Venkatraman here. Raja Venkatraman is co-founder, NeoTrader. His Sebi-registered research analyst registration no. is INH000016223. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantees performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
25-04-2025
- Business
- Time of India
Buy J B Chemicals & Pharmaceuticals, target price Rs 2,225: JM Financial
JM Financial maintains a buy call on J B Chemicals & Pharmaceuticals, setting a target price of Rs 2,225. The brokerage believes a ban on ranitidine products, including J B Chemical's Rantac, is unlikely despite concerns over NDMA levels. J B Chemicals, incorporated in 1976, is a Mid Cap company with a market cap of Rs 25050.02 crore. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads (Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.)
Business Standard
21-04-2025
- Business
- Business Standard
JB Chemicals & Pharma receives USFDA approval for Bisoprolol Tablets
JB Chemicals & Pharmaceuticals announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Bisoprolol Tablets USP, 5 mg, and 10 mg. The approved product is the generic version of Zebeta (marketed by Teva Pharmaceuticals) and is indicated for the management of hypertension. JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radio-diagnostics, APIs, and intermediates. The company's consolidated net profit jumped 21.7% to Rs 162.49 crore on a 14.1% rise in net sales to Rs 963.49 crore in Q3 FY25 over Q3 FY24. Shares of JB Chemicals & Pharmaceuticals rose 0.47% to Rs 1,652.95 on the BSE.
